Loading
Mesenchymal stem-like was one of the six original subtypes of triple-negative breast cancer, marked by stem-cell and low-proliferation genes. Five years later the same group showed the signal came from stromal cells mixed into the sample rather than the cancer cells, so the label describes a tumour environment rather than a tumour.
Lehmann 2011 separated a mesenchymal stem-like (MSL) cluster from the mesenchymal cluster by lower expression of proliferation genes and enrichment for genes of mesenchymal stem cells, angiogenesis and growth factor signalling; representative cell lines responded to the PI3K/mTOR inhibitor NVP-BEZ235 and to dasatinib (Lehmann 2011). Using histopathological quantification and laser-capture microdissection, the 2016 refinement showed that the MSL transcripts were contributed by tumour-associated stromal cells, as the immunomodulatory transcripts were by infiltrating lymphocytes, and collapsed the classification to four tumour-specific subtypes (Lehmann 2016). The page stays because the label persists in papers and reports; a tumour once called MSL would now be assigned to the mesenchymal or another intrinsic subtype, and its low proliferation and stromal richness match the claudin-low phenotype described by Fougner 2020.
A research classification by gene expression (Lehmann 2011, refined 2016), not a test the NHS runs; treatment follows the triple-negative rows on the parent page.
One of the six 2011 Lehmann subtypes; dropped as a tumour-intrinsic subtype in 2016 when its signal was traced to stromal cells.
Most cancers start in the ducts and drain first to the axillary nodes, which is why the armpit is checked and a sentinel node is sampled.
Same organ: Triple-negative breast cancer (TNBC), Breast cancer (all types), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, Male breast cancer, Ductal carcinoma in situ (DCIS), High-risk early HR-positive breast cancer, HR-positive metastatic breast cancer after CDK4/6 inhibitors, HER2-low and HER2-ultralow metastatic breast cancer, Early HER2-positive breast cancer, HER2-positive breast cancer with brain metastases, Early triple-negative breast cancer, Metastatic triple-negative breast cancer, Basal-like 1 triple-negative breast cancer (BL1), Basal-like 2 triple-negative breast cancer (BL2), Mesenchymal triple-negative breast cancer (M), Luminal androgen receptor triple-negative breast cancer (LAR), Immunomodulatory triple-negative breast cancer (IM), Metaplastic breast carcinoma, Carcinoma with medullary pattern (medullary breast cancer), Adenoid cystic carcinoma of the breast, Apocrine carcinoma of the breast, Secretory carcinoma of the breast, BRCA-associated triple-negative breast cancer, Inflammatory breast cancer, Paget disease of the nipple, Phyllodes tumour of the breast, Invasive lobular carcinoma of the breast, Invasive breast carcinoma of no special type (invasive ductal carcinoma), Tubular carcinoma of the breast, Mucinous carcinoma of the breast, Papillary carcinomas of the breast (encapsulated, solid and invasive papillary), Invasive cribriform carcinoma of the breast, Invasive breast carcinoma with medullary pattern (medullary carcinoma), Invasive micropapillary carcinoma of the breast, Neuroendocrine neoplasms of the breast, Lobular carcinoma in situ (LCIS)
As for triple-negative disease; the label has no treatment consequence.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this cancer: (TITLE:"Mesenchymal stem-like triple-negative breast cancer" OR ABSTRACT:"Mesenchymal stem-like triple-negative breast cancer" OR TITLE:"MSL" OR ABSTRACT:"MSL" OR TITLE:"MSL subtype" OR ABSTRACT:"MSL subtype" OR TITLE:"Mesenchymal stem-like TNBC" OR ABSTRACT:"Mesenchymal stem-like TNBC") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Mesenchymal stem-like triple-negative breast cancer (MSL), not a curated reading list.
The targets of this cancer's medicines and the ones linked to it directly.
Cases by country, the UK and NHS pathway and other country lenses, and the expert centres with trials on record.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Persistent headache with extreme tiredness, nausea, dizziness on standing or low blood pressure. Vomiting, severe weakness or collapse is adrenal crisis.
No pharmacokinetic interactions expected (antibody). See the irAE guide for toxicity management.
Immunotherapy can attack hormone-producing glands: most often the thyroid (usually ending in an under-active thyroid needing lifelong tablets), and less often the pituitary (hypophysitis) or adrenal glands, which can be life-threatening if missed.
See all on the product pages:Pembrolizumab·Printable cards in the navigator
Newly diagnosed? Read the first 60 days with Mesenchymal stem-like triple-negative breast cancer, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.